20S Proteasome β3 Inhibitors are a distinct class of chemical compounds that specifically target the β3 subunit of the 20S proteasome, a core particle of the proteasome complex involved in the degradation of ubiquitinated proteins. The 20S proteasome is a cylindrical structure composed of four stacked rings, with the β3 subunit being one of the critical components within the inner rings responsible for proteolytic activity. Inhibitors targeting the β3 subunit function by binding to specific sites on this subunit, thereby interfering with its proteolytic function. This binding can induce conformational changes in the β3 subunit, leading to alterations in its catalytic activity and, consequently, affecting the overall function of the proteasome. The specificity of these inhibitors is often achieved through precise molecular interactions, where the chemical structure of the inhibitor is designed to fit into the active site or allosteric sites of the β3 subunit, thus preventing substrate proteins from being efficiently degraded.
The chemical nature of 20S Proteasome β3 Inhibitors is characterized by features that enhance their binding affinity and specificity for the β3 subunit. These features may include hydrophobic regions that interact with non-polar residues within the β3 subunit or polar functional groups that form hydrogen bonds with key amino acids in the active site. Additionally, the inhibitors' physicochemical properties, such as molecular size, solubility, and stability, are carefully optimized to ensure that they can effectively reach and bind to the β3 subunit within the proteasome complex. The kinetics of inhibitor binding, including the rates of association and dissociation, are crucial in determining the duration and extent of inhibition, as these factors influence the ability of the inhibitor to modulate proteasome activity under various conditions. By studying the interactions between 20S Proteasome β3 Inhibitors and the β3 subunit, researchers can gain a deeper understanding of the mechanisms that regulate protein degradation and the role of the proteasome in maintaining cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib binds to the catalytic site of the 20S proteasome with high specificity, particularly targeting the chymotrypsin-like activity. It could possibly inhibit PSMB3 by reversibly inhibiting this activity, thereby affecting the proteasome's ability to degrade proteins. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib inhibits the proteasome by covalently modifying the N-terminal threonine on its catalytic subunits. This action impairs the overall proteolytic activity of the proteasome, which could possibly inhibit PSMB3. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin irreversibly binds to and inhibits the activity of the proteasome's catalytic β subunits. This binding impairs the proteolytic function of PSMB3, reducing the proteasome's ability to degrade proteins and could possibly inhibit PSMB3. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
ONX-0914 specifically inhibits the LMP7 subunit of the immunoproteasome, and while not a direct inhibitor of PSMB3, its inhibition of proteasome activity can broadly affect the function of related proteasome subunits, including PSMB3, and could possibly inhibit PSMB3. | ||||||